Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 22, Issue 14
  5. Article
Volume 22, Issue 14
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background

Excessive free radicals are implicated in the pathophysiology of tardive dyskinesia (TD), and extract (EGb761) scavenges free radicals, thereby enhancing antioxidant enzymes such as mitochondrial manganese superoxide dismutase (). This study examined whether EGb761 treatment would improve TD symptoms and increase activity, particularly in TD patients with specific Val-9Ala genotype.

Methods

An EGb761 (240 mg/day) 12-week double-blind clinical trial with 157 TD patients was randomized. The severity of TD was measured by the Abnormal Involuntary Movement Scale (AIMS) and plasma activity was assayed before and after 12 weeks of treatment. Further, in an expanded sample, we compared activity in 159 TD, 227 non-TD and 280 healthy controls, as well as the allele frequencies and genotypes for the Ala-9Val polymorphism in 352 TD, 486 non-TD and 1150 healthy controls.

Results

EGb761 significantly reduced TD symptoms and increased activity in TD patients compared to placebo (both < 0.01). Moreover, we found an interaction between genotype and treatment response ( < 0.001). Furthermore, in the EGb761 group, patients carrying the Ala allele displayed a significantly lower AIMS total score than patients with the Val/Val genotype. In addition, activity was significantly lower at baseline in TD patients compared with healthy controls or non-TD patients.

Conclusion

EGb761 treatment enhanced low activity in TD patients and produced greater improvement in TD symptoms in patients with the Ala allele of the Ala-9Val polymorphism.

Clinical Trial Registration No

NCT00672373.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X22666240530095721
2024-12-01
2024-11-26

  • From This Site

    /content/journals/cn/10.2174/1570159X22666240530095721
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CarbonM. KaneJ.M. LeuchtS. CorrellC.U. Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: A meta‐analysis.World Psychiatry201817333034010.1002/wps.20579 30192088
     [Google Scholar]
  2. LohrJ.B. KuczenskiR. NiculescuA.B. Oxidative mechanisms and tardive dyskinesia.CNS Drugs2003171476210.2165/00023210‑200317010‑00004 12467492
     [Google Scholar]
  3. ChoC.H. LeeH.J. Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence.Prog. Neuropsychopharmacol. Biol. Psychiatry20134620721310.1016/j.pnpbp.2012.10.018 23123399
     [Google Scholar]
  4. BishnoiM. BoparaiR.K. An animal model to study the molecular basis of tardive dyskinesia.Methods Mol. Biol.201282919320110.1007/978‑1‑61779‑458‑2_12 22231815
     [Google Scholar]
  5. ZhangX.Y. ChenD.C. XiuM.H. YangF.D. TanY. LuoX. ZuoL. KostenT.A. KostenT.R. Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.Schizophr. Bull.201440359260110.1093/schbul/sbt045 23588476
     [Google Scholar]
  6. ZhangX.Y. TanY.L. ZhouD.F. CaoL.Y. WuG.Y. HaileC.N. KostenT.A. KostenT.R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia.J. Clin. Psychiatry200768575476010.4088/JCP.v68n0513 17503985
     [Google Scholar]
  7. FactorS.A. Management of Tardive Syndrome: Medications and surgical treatments.Neurotherapeutics20201741694171210.1007/s13311‑020‑00898‑3 32720245
     [Google Scholar]
  8. Soares-WeiserK. MaayanN. BergmanH. Vitamin E for antipsychotic-induced tardive dyskinesia.Cochrane Database Syst. Rev.201811CD000209 29341067
     [Google Scholar]
  9. FedotaJ.R. MatousA.L. SalmeronB.J. GuH. RossT.J. SteinE.A. Insula demonstrates a non-linear response to varying demand for cognitive control and weaker resting connectivity with the executive control network in smokers.Neuropsychopharmacology201641102557256510.1038/npp.2016.62 27112116
     [Google Scholar]
  10. LoonenA.J.M. IvanovaS.A. New insights into the mechanism of drug-induced dyskinesia.CNS Spectr.2013181152010.1017/S1092852912000752 23593652
     [Google Scholar]
  11. MahmoudiS. LévesqueD. BlanchetP.J. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.Mov. Disord.20142991125113310.1002/mds.25909 24838395
     [Google Scholar]
  12. MahadikS.P. MukherjeeS. Free radical pathology and antioxidant defense in Schizophrenia: A review.Schizophr. Res.199619111710.1016/0920‑9964(95)00049‑6 9147491
     [Google Scholar]
  13. SakamotoT. ImaiH. Hydrogen peroxide produced by superoxide dismutase SOD-2 activates sperm in Caenorhabditis elegans.J. Biol. Chem.201729236148041481310.1074/jbc.M117.788901 28724632
     [Google Scholar]
  14. TsaiG. GoffD.C. ChangR.W. FloodJ. BaerL. CoyleJ.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.Am. J. Psychiatry199815591207121310.1176/ajp.155.9.1207 9734544
     [Google Scholar]
  15. LindholmE. EkholmB. ShawS. JalonenP. JohanssonG. PetterssonU. SherringtonR. AdolfssonR. JazinE. A schizophrenia-susceptibility locus at 6q25, in one of the world’s largest reported pedigrees.Am. J. Hum. Genet.20016919610510.1086/321288 11389481
     [Google Scholar]
  16. Shimoda-MatsubayashiS. MatsumineH. KobayashiT. Nakagawa-HattoriY. ShimizuY. MizunoY. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson’s disease.Biochem. Biophys. Res. Commun.1996226256156510.1006/bbrc.1996.1394 8806673
     [Google Scholar]
  17. RosenblumJ.S. GilulaN.B. LernerR.A. On signal sequence polymorphisms and diseases of distribution.Proc. Natl. Acad. Sci. 19969394471447310.1073/pnas.93.9.4471 8633092
     [Google Scholar]
  18. HoriH. OhmoriO. ShinkaiT. KojimaH. OkanoC. SuzukiT. NakamuraJ. Manganese superoxide dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia.Neuropsychopharmacology200023217017710.1016/S0893‑133X(99)00156‑6 10882843
     [Google Scholar]
  19. GałeckiP. PietrasT. SzemrajJ. Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland.Psychiatr. Pol.2006405937948 17217237
     [Google Scholar]
  20. ZhangZ. ZhangX. HouG. ShaW. ReynoldsG.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.J. Psychiatr. Res.200236531732410.1016/S0022‑3956(02)00007‑9 12127599
     [Google Scholar]
  21. AkyolO. YanikM. ElyasH. NamliM. CanatanH. AkinH. YuceH. YilmazH.R. TutkunH. SogutS. HerkenH. ÖzyurtH. SavasH.A. ZorogluS.S. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia.Prog. Neuropsychopharmacol. Biol. Psychiatry200529112313110.1016/j.pnpbp.2004.10.014 15610954
     [Google Scholar]
  22. PaeC.U. KimT.S. PatkarA.A. KimJ.J. LeeC.U. LeeS.J. JunT.Y. LeeC. PaikI.H. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia.Psychiatry Res.20071531778110.1016/j.psychres.2006.04.011 17582511
     [Google Scholar]
  23. HitzerothA. NiehausD.J.H. KoenL. BotesW.C. DeleuzeJ.F. WarnichL. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.Prog. Neuropsychopharmacol. Biol. Psychiatry200731366467210.1016/j.pnpbp.2006.12.019 17291655
     [Google Scholar]
  24. KangS.G. ChoiJ.E. AnH. ParkY.M. LeeH.J. HanC. KimY.K. KimS.H. ChoS.N. JoeS.H. JungI.K. KimL. LeeM.S. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients.Prog. Neuropsychopharmacol. Biol. Psychiatry20083281844184710.1016/j.pnpbp.2008.08.013 18790709
     [Google Scholar]
  25. ThelmaB.K. TiwariA.K. DeshpandeS.N. LererB. NimgaonkarV.L. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: Role of oxidative stress pathway genes.Schizophr. Res.2007921-327827910.1016/j.schres.2006.12.019 17317105
     [Google Scholar]
  26. BakkerP.R. van HartenP.N. van OsJ. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-analysis of pharmacogenetic interactions.Mol. Psychiatry200813554455610.1038/sj.mp.4002142 18180754
     [Google Scholar]
  27. WangD.F. CaoB. XuM.Y. LiuY.Q. YanL.L. LiuR. WangJ.Y. LuQ.B. Meta-analyses of manganese superoxide dismutase activity, gene Ala-9Val polymorphism, and the risk of schizophrenia.Medicine 20159436e150710.1097/MD.0000000000001507 26356721
     [Google Scholar]
  28. ZhangZ.J. ZhangX.B. HouG. YaoH. ReynoldsG.P. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia.Psychiatr. Genet.200313318719210.1097/00041444‑200309000‑00010 12960753
     [Google Scholar]
  29. LiuH. WangC. ChenP.H. ZhangB.S. ZhengY.L. ZhangC.X. MengH.Q. WangY. ChenD.C. XiuM.H. KostenT.R. ZhangX.Y. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients.Prog. Neuropsychopharmacol. Biol. Psychiatry201034469269610.1016/j.pnpbp.2010.03.026 20346996
     [Google Scholar]
  30. PontoL.B. SchultzS. Ginkgo biloba extract: Review of CNS effects.Ann. Clin. Psychiatry200315210911910.3109/10401230309085676 12938868
     [Google Scholar]
  31. DeFeudisF. DrieuK. Ginkgo biloba extract (EGb 761) and CNS functions: Basic studies and clinical applications.Curr. Drug Targets200011255810.2174/1389450003349380 11475535
     [Google Scholar]
  32. ZhangW.F. TanY.L. ZhangX.Y. ChanR.C.K. WuH.R. ZhouD.F. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: A randomized, double-blind, placebo-controlled trial.J. Clin. Psychiatry201172561562110.4088/JCP.09m05125yel 20868638
     [Google Scholar]
  33. MontesP. Ruiz-SanchezE. RojasC. RojasP. Ginkgo biloba extract 761: A review of basic studies and potential clinical use in psychiatric disorders.CNS Neurol. Disord. Drug Targets201514113214910.2174/1871527314666150202151440 25642989
     [Google Scholar]
  34. IhlR. Effects of Ginkgo biloba extract EGb761® in dementia with neuropsychiatric features: Review of recently completed randomised, controlled trials.Int. J. Psychiatry Clin. Pract.201317S181410.3109/13651501.2013.814796 23808613
     [Google Scholar]
  35. GauthierS. SchlaefkeS. Efficacy and tolerability of Ginkgo biloba extract EGb761® in dementia: A systematic review and meta-analysis of randomized placebo-controlled trials.Clin. Interv. Aging201492065207710.2147/CIA.S72728 25506211
     [Google Scholar]
  36. TanM.S. YuJ.T. TanC.C. WangH.F. MengX.F. WangC. JiangT. ZhuX.C. TanL. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: A systematic review and meta-analysis.J. Alzheimers Dis.201443258960310.3233/JAD‑140837 25114079
     [Google Scholar]
  37. JiH. ZhouX. WeiW. WuW. YaoS. Ginkgol Biloba extract as an adjunctive treatment for ischemic stroke.Medicine 2020992e1856810.1097/MD.0000000000018568 31914035
     [Google Scholar]
  38. DiamondB.J. BaileyM.R. Ginkgo biloba.Psychiatr. Clin. North Am.2013361738310.1016/j.psc.2012.12.006 23538078
     [Google Scholar]
  39. ZhengW. XiangY.Q. NgC. UngvariG. ChiuH. XiangY.T. Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of randomized controlled trials.Pharmacopsychiatry201649310711110.1055/s‑0042‑102884 26979525
     [Google Scholar]
  40. KamI.W. ChungW.S.D. LiuS. FongS. The Chinese-bilingual SCID-I/P project: Stage 1 - Reliability for mood disorders and schizophrenia.Hong Kong J. Psychiatry2003131
     [Google Scholar]
  41. KaneJ.M. KaneJ.M. Research diagnoses for tardive dyskinesia.Arch. Gen. Psychiatry198239448648710.1001/archpsyc.1982.04290040080014 6121550
     [Google Scholar]
  42. FanB. The Chinese version of the Abnormal Involuntary Movement Scale (AIMS).198428081
     [Google Scholar]
  43. SI T.; Yang, J.; Shu, L. The reliability, validity of PANSS and its implication. Chinese Mental Health Journal1992199212
     [Google Scholar]
  44. ŌyanaguiY. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity.Anal. Biochem.1984142229029610.1016/0003‑2697(84)90467‑6 6099057
     [Google Scholar]
  45. WuJ.Q. KostenT.R. ZhangX.Y. Free radicals, antioxidant defense systems, and schizophrenia.Prog. Neuropsychopharmacol. Biol. Psychiatry20134620020610.1016/j.pnpbp.2013.02.015 23470289
     [Google Scholar]
  46. MahadevanS. ParkY. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses.J. Food Sci.2008731R14R1910.1111/j.1750‑3841.2007.00597.x 18211362
     [Google Scholar]
  47. LoonenA.J.M. van PraagH.M. Measuring movement disorders in antipsychotic drug trials: The need to define a new standard.J. Clin. Psychopharmacol.200727542343010.1097/jcp.0b013e31814f1105 17873670
     [Google Scholar]
  48. KaneJ.M. CorrellC.U. NierenbergA.A. CaroffS.N. SajatovicM. Revisiting the abnormal involuntary movement scale. J. Clin. Psychiatry,201879317cs1195910.4088/JCP.17cs1195929742330
     [Google Scholar]
  49. Shimoda-MatsubayashiS. HattoriT. MatsumineH. ShinoharaA. YoritakaA. MoriH. KondoT. ChibaM. MizunoY. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson’s disease and control.Neurology19974951257126210.1212/WNL.49.5.1257 9371904
     [Google Scholar]
  50. BrescianiG. CruzI.B.M. de PazJ.A. CuevasM.J. González-GallegoJ. The MnSOD Ala16Val SNP: Relevance to human diseases and interaction with environmental factors.Free Radic. Res.2013471078179210.3109/10715762.2013.836275 23952573
     [Google Scholar]
  51. ZengK. LiM. HuJ. MahamanY.A.R. BaoJ. HuangF. XiaY. LiuX. WangQ. WangJ.Z. YangY. LiuR. WangX. Ginkgo biloba extract EGb761 attenuates hyperhomocysteinemia-induced AD like Tau hyperphosphorylation and cognitive impairment in rats.Curr. Alzheimer Res.2017151899910.2174/1567205014666170829102135 28847282
     [Google Scholar]
  52. KwonK.J. LeeE.J. ChoK.S. ChoD.H. ShinC.Y. HanS.H. Ginkgo biloba extract (Egb761) attenuates zinc-induced tau phosphorylation at Ser262 by regulating GSK3β activity in rat primary cortical neurons.Food Funct.2015662058206710.1039/C5FO00219B 26032477
     [Google Scholar]
  53. LoonenA.J.M. DoorschotC.H. van HemertD.A. OostelbosM.C.J.M. SijbenA.E.S. The schedule for the assessment of drug-induced movement disorders (SADIMoD): Inter-rater reliability and construct validity.Int. J. Neuropsychopharmacol.20014434736010.1017/S1461145701002589 11806860
     [Google Scholar]
  54. LoonenA.J.M. DoorschotC.H. van HemertD.A. OostelbosM.C.J.M. SijbenA.E.S. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): Test-retest reliability and concurrent validity.Int. J. Neuropsychopharmacol.20003428529610.1017/S1461145700002066 11343606
     [Google Scholar]
  55. StacyM. SajatovicM. KaneJ.M. CutlerA.J. LiangG.S. O’BrienC.F. CorrellC.U. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.Mov. Disord.20193481203120910.1002/mds.27769 31234240
     [Google Scholar]
/content/journals/cn/10.2174/1570159X22666240530095721
Loading
Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial
Curr. Neuropharmacol. 22, 2443 (2024); https://doi.org/10.2174/1570159X22666240530095721
/content/journals/cn/10.2174/1570159X22666240530095721
/content/journals/cn/10.2174/1570159X22666240530095721
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): genotype; ginkgo biloba extract; pharmacogenetics; plasma MnSOD; Schizophrenia; tardive dyskinesia

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test